These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21315859)

  • 1. [Design and validation of a questionnaire to measure treatment satisfaction in patients with moderate-to-severe psoriasis: the NEODERMA study].
    Ribera M; Daudén E; Puig L; Briones VG; Herranz JM; Bordas X; Vanaclocha F;
    Actas Dermosifiliogr; 2011 Jan; 102(1):28-38. PubMed ID: 21315859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
    Lecha M; Mirada A; López S; Artés M;
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis.
    Gottlieb A; Feng J; Harrison DJ; Globe D
    J Am Acad Dermatol; 2010 Oct; 63(4):580-6. PubMed ID: 20599294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial.
    Langley RG; Paller AS; Hebert AA; Creamer K; Weng HH; Jahreis A; Globe D; Patel V; Orlow SJ
    J Am Acad Dermatol; 2011 Jan; 64(1):64-70. PubMed ID: 20619489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of moderate-to-severe psoriasis in clinical practice: a survey of Spanish dermatologists].
    Moreno-Ramírez D; Fonseca E; Herranz P; Ara M
    Actas Dermosifiliogr; 2010 Dec; 101(10):858-65. PubMed ID: 21159262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cultural adaptation to Spanish and validation of the Gastrointestinal Short Form Questionnaire].
    Ruiz Díaz MA; Suárez Parga JM; Pardo Merino A; García Vargas M; Pascual Renedo V
    Gastroenterol Hepatol; 2009 Jan; 32(1):9-21. PubMed ID: 19174094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
    Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
    J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
    J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life.
    Ho SG; Yeung CK; Chan HH
    Clin Exp Dermatol; 2010 Oct; 35(7):717-22. PubMed ID: 19925489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis.
    Seston EM; Ashcroft DM; Griffiths CE
    Arch Dermatol; 2007 Sep; 143(9):1175-9. PubMed ID: 17875880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
    Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Norwegian version of the Quality of Life Scale (QOLS-N). A validation and reliability study in patients suffering from psoriasis.
    Wahl A; Burckhardt C; Wiklund I; Hanestad BR
    Scand J Caring Sci; 1998; 12(4):215-22. PubMed ID: 10067647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of bexarotene gel 1% in psoriasis.
    Breneman D; Sheth P; Berger V; Naini V; Stevens V
    J Drugs Dermatol; 2007 May; 6(5):501-6. PubMed ID: 17679184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth".
    Radtke MA; Schäfer I; Blome C; Augustin M
    Eur J Dermatol; 2013 Apr; 23(2):212-7. PubMed ID: 23587940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Even well-controlled psoriasis patients have unmet treatment needs regardless of disease severity.
    Vaidya TS; Anderson KL; Feldman SR
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of 15% azelaic acid in psoriasis vulgaris: a randomized, controlled clinical trial.
    Iraji F; Faghihi G; Siadat AH; Enshaieh S; Shahmoradi Z; Joia A; Soleimani F
    J Drugs Dermatol; 2010 Aug; 9(8):964-8. PubMed ID: 20684146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire.
    Piault E; Evans CJ; Espindle D; Kopp Z; Brubaker L; Abrams P
    Neurourol Urodyn; 2008; 27(3):179-90. PubMed ID: 17565727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.